

Analysis of the Performance of the Software/Hardware Product MyDiaBase+RxChecker for Assessing Treatment Regimens

Danny Petrasek, M.D., Ph.D., and Marissa Bidner

Abstract

In 2008, the Action to Control Cardiovascular Risk in Diabetes trial was halted due to an unexpected number of deaths in the intensive treatment group (aiming for hemoglobin A1c levels less than 6%). Hypoglycemic episodes were thought by some to be a contributing cause, underscoring again the challenge of maintaining tight control while avoiding dangerous excursions into hypoglycemic territory. Albisser and colleagues present a set of articles in this issue of *Journal of Diabetes Science and Technology* that describe a clinical product developed specifically for this timeless clinical conundrum.

J Diabetes Sci Technol 2009;3(3):533-535

Author Affiliation: California Institute of Technology (Caltech), Los Angeles, California

Abbreviations: (ACCORD) Action to Control Cardiovascular Risk in Diabetes, (HbA1c) hemoglobin A1c, (DM) diabetes mellitus

Keywords: managing hypoglycemia, telemedicine

Corresponding Author: Danny Petrasek, M.D., Ph.D., Faculty Associate in Bioengineering and Applied and Computational Mathematics, California Institute of Technology (Caltech), 1412 N. Crescent Heights Blvd., #101, Los Angeles, CA 90046; email address danny_petrasek@yahoo.com